Mental health · Bellevue, WA
Mental health studies in Bellevue, WA
27 recruiting studies have a site in Bellevue.
27 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
Draig Therapeutics Ltd
- Location
- Bellevue, WA + 19 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Draig Therapeutics Ltd
- Location
- Bellevue, WA + 18 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
Eli Lilly and Company
- Location
- Bellevue, WA + 19 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study of Brenipatide in Adult Participants With Schizophrenia
Eli Lilly and Company
- Location
- Bellevue, WA + 31 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 2
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
Alkermes, Inc.
- Location
- Bellevue, WA + 17 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
Eli Lilly and Company
- Location
- Bellevue, WA + 28 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Eli Lilly and Company
- Location
- Bellevue, WA + 31 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Bellevue, WA + 33 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
MapLight Therapeutics
- Location
- Bellevue, WA + 32 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Intra-Cellular Therapies, Inc.
- Location
- Bellevue, WA + 17 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Intra-Cellular Therapies, Inc.
- Location
- Bellevue, WA + 19 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc.
- Location
- Bellevue, WA + 46 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Bellevue, WA + 33 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.
- Location
- Bellevue, WA + 24 other US sites
- Eligibility basics
- Any age listed
- RecruitingPhase 2
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.
- Location
- Bellevue, WA + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Bellevue, WA + 44 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Bellevue, WA + 18 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
Janssen Research & Development, LLC
- Location
- Bellevue, WA + 6 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Vanda Pharmaceuticals
- Location
- Bellevue, WA + 24 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Bellevue, WA + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
AbbVie
- Location
- Bellevue, WA + 32 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
LB Pharmaceuticals Inc.
- Location
- Bellevue, WA + 25 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
AbbVie
- Location
- Bellevue, WA + 46 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
AbbVie
- Location
- Bellevue, WA + 32 other US sites
- Eligibility basics
- Ages 18–65
Who these studies look for
Studies usually require a confirmed diagnosis and stable circumstances, and they monitor safety closely. If you are in crisis, contact a crisis line or emergency services rather than a study.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.